HUNG-CHIH YANGJIA-HORNG KAO2021-07-122021-07-1220151759-5045https://www.scopus.com/inward/record.uri?eid=2-s2.0-84924262597&doi=10.1038%2fnrgastro.2015.8&partnerID=40&md5=20c1c38f12eb74050d049a472046c822https://scholars.lib.ntu.edu.tw/handle/123456789/570884[SDGs]SDG3entecavir; hepatitis B surface antigen; hepatitis B vaccine; hepatitis B(e) antigen; interferon; nucleotide derivative; T lymphocyte receptor; hepatitis B vaccine; CD8+ T lymphocyte; cellular immunity; disease control; hepatitis B; Hepatitis B virus; human; immunotherapy; innate immunity; liver cell; nonhuman; priority journal; Short Survey; viral clearance; virus load; virus replication; animal; disease model; Hepatitis B, Chronic; immunology; mouse; Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Miceshort survey10.1038/nrgastro.2015.8256232022-s2.0-84924262597